Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.3
3.2
Journals
Life
Special Issues
Current Advances in Lung Cancer Diagnosis and Treatment
share announcement

Current Advances in Lung Cancer Diagnosis and Treatment

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 2310

Special Issue Editors

Dr. Hakyoung Kim

E-Mail Website
Guest Editor
Department of Radiation Oncology, Korea University Guro Hospital, Korea University College of Medicine, 148 Gurodong-ro, Guro-gu, Seoul 08308, Republic of Korea
Interests: non-small cell lung cancer; small cell lung cancer; diagnosis; lung disease; radiotherapy; systemic therapy; survival; complication; biomarker
Dr. Daesik Yang

E-Mail Website
Guest Editor
Department of Radiation Oncology, Korea University Guro Hospital, Korea University College of Medicine, 148 Gurodong-ro, Guro-gu, Seoul 08308, Republic of Korea
Interests: clinical oncology; radiation oncology
Dr. Zhiwei Hu

E-Mail Website
Guest Editor
Pelotonia Institute for Immuno-Oncology, Arthur G. James Comprehensive Cancer Center, Ohio State University College of Medicine, Columbus, OH 43210, USA
Interests: targeted immunotherapy; targeted photodynamic therapy; vascular tissue; necrosis; neoplasms; macular degeneration; choroidal neovascularization; lung neoplasms; breast neoplasms; neoplasm metastasis; melanoma; tumor immunology; immunotherapy, particularly antibody and CAR-NK cell immunotherapy; photodynamic therapy; gene therapy; cancer pathology; tumor angiogenesis; tumor microenvironment; immune cells; NK cells; MDSC; cancer stem cells
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Remarkable advances in systemic agents, such as targeted therapies and immuno-oncological agents, are significantly changing the treatment methods for lung cancer patients based on the stage they are in.

In particular, this enables more aggressive local therapy in the treatment of stage IV lung cancer. The current National Comprehensive Cancer Network guidelines also recommend consolidative local therapy for selected patients with localized metastatic lung cancer who have responded to prior chemotherapy and have a limited extra-thoracic tumor burden. However, in actual clinical settings, there are still no consistent treatment principles for defining criteria for localized metastasis, as well as for evaluating and treating oligo-progression. In active local treatment, it is important to consider the patient's general condition, such as the presence of any underlying lung disease and the potential side effects of the treatment.

In this Special Issue, we will compile studies related to improving clinical outcomes or predicting side effects, aligned with the latest knowledge on lung cancer treatment.

Dr. Hakyoung Kim
Dr. Daesik Yang
Dr. Zhiwei Hu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • lung cancer
  • underlying lung disease
  • radiotherapy
  • systemic therapy
  • survival outcomes
  • complication
  • biomarkers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 472 KiB  
Article
Comparison of Lung-RADS Version 2022 and British Thoracic Society Guidelines in Classifying Solid Pulmonary Nodules Detected at Lung Cancer Screening CT
by Claudiu Avram, Alexandru Ovidiu Mederle, Adelina Mavrea, Paula Irina Barata and Raul Patrascu
Life 2025, 15(1), 14; https://doi.org/10.3390/life15010014 - 27 Dec 2024
Cited by 1 | Viewed by 929
Abstract
Background and Objectives: Lung cancer screening is critical for early detection and management, particularly through the use of computed tomography (CT). This study aims to compare the Lung Imaging Reporting and Data System (Lung-RADS) Version 2022 with the British Thoracic Society (BTS) guidelines [...] Read more.
Background and Objectives: Lung cancer screening is critical for early detection and management, particularly through the use of computed tomography (CT). This study aims to compare the Lung Imaging Reporting and Data System (Lung-RADS) Version 2022 with the British Thoracic Society (BTS) guidelines in classifying solid pulmonary nodules detected at lung cancer screening CT examinations. Materials and Methods: This retrospective study included 224 patients who underwent lung cancer screening CT between 2016 and 2022 and had a reported solid pulmonary nodule. A fellowship-trained thoracic radiologist reviewed the CT images, characterizing nodules by size, location, margins, attenuation, calcification, growth at follow-up, and final pathologic diagnosis if malignant. The sensitivity and specificity of Lung-RADS Version 2022 in detecting malignant nodules were compared with those of the BTS guidelines using the McNemar test. Results: Of the 224 patients, 198 (88%) had nodules deemed benign, while 26 (12%) had malignant nodules. The Lung-RADS Version 2022 resulted in higher specificity than the BTS guidelines (85% vs. 65%, p < 0.001), without sacrificing sensitivity (92% for both). Nodules larger than 8 mm, spiculated margins, upper lobe location, and interval growth were associated with higher malignancy risk (p < 0.01). Conclusions: Compared with the BTS guidelines, Lung-RADS Version 2022 reduces the number of false-positive screening CT examinations while maintaining high sensitivity for detecting malignant solid pulmonary nodules. Full article
(This article belongs to the Special Issue Current Advances in Lung Cancer Diagnosis and Treatment)
►▼ Show Figures

Figure 1

10 pages, 1539 KiB  
Article
Completing the Puzzle: Determinants, Comorbidities and Complications for Different Lung Cancer Subtypes: A Pilot Study
by Corina Eugenia Budin, Iuliu Gabriel Cocuz, Adrian-Horațiu Sabău, Raluca Niculescu, Cristian Cazacu, Edith-Simona Ianoși and Ovidiu Simion Cotoi
Life 2024, 14(12), 1611; https://doi.org/10.3390/life14121611 - 5 Dec 2024
Viewed by 939
Abstract
Background: Lung cancer remains one of the leading causes of cancer-related mortality worldwide, with multiple independent risk factors contributing to its development. The objective of this study was represented by the impact of independent risk factors, such as smoking, anemia, cachexia or COPD [...] Read more.
Background: Lung cancer remains one of the leading causes of cancer-related mortality worldwide, with multiple independent risk factors contributing to its development. The objective of this study was represented by the impact of independent risk factors, such as smoking, anemia, cachexia or COPD (chronic obstructive pulmonary disease) for lung cancer development. Methods: We conducted a retrospective study, and we analyzed a database of 412 patients hospitalized between 1 February and 31 December 2023 in the Pulmonology Department of the Mureș County Clinical Hospital. Following the analysis of the inclusion and exclusion criteria, the final analyzed group included 115 patients. Results: From the study group, 88 patients were diagnosed with non-small cell lung cancer and 27 with small cell lung cancer. Of the non-small cell lung cancer patients, 50% had adenocarcinoma and 50% had squamous cell carcinoma. Chronic obstructive pulmonary disease and cardiovascular diseases predominate as concomitant pathologies, with 82 and 81 cases identified among the patients evaluated, respectively. The incidence of diabetes mellitus was n = 20 for the patients, followed by asthma and other neoplasms. The body mass index was also analyzed with an average of 24.6. Body mass index does not correlate with histological type. The mean hemoglobin value in the group of patients was 12.8, and this could not be correlated with the histopathological type. Conclusions: Chronic obstructive pulmonary disease and lung cancer may just be two different clinical presentations based on the same etiological factors, which also have a lot of overlapping pathophysiological mechanisms. Therefore, Chronic obstructive pulmonary disease represents an individual risk factor for developing lung cancer. Smoking, as well as anemia, cachexia or other comorbidities (COPD), are individual risk factors for lung cancer. Full article
(This article belongs to the Special Issue Current Advances in Lung Cancer Diagnosis and Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop